Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:15:28.693Z.
Calculation as of: 2026-10-06T21:15:28.693Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Kalaris Therapeutics Inc
Market Cap
$58.06M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.29M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.76M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.43M
Operating Cash Flow Yield
N/A
TTM Avg
1.11%
3Y Avg
1.11%
5Y Avg
1.11%
Market Cap
$58.44M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.01M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$59.18M
Operating Cash Flow Yield
N/A
TTM Avg
39.02%
3Y Avg
39.02%
5Y Avg
39.02%
Market Cap
$60.02M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $58.06M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A | 1.11% | 1.11% | 1.11% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A | 39.02% | 39.02% | 39.02% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
